BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24549815)

  • 1. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
    Zhang H; Li Z; Wang K
    Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
    Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non‑small cell lung cancer cells in vitro and in vivo.
    Zhang H; Li Z; Wang K; Ren P
    Oncol Rep; 2015 Mar; 33(3):1079-88. PubMed ID: 25524805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
    Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
    Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
    Yang Q; Zhang S; Kang M; Dong R; Zhao J
    Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
    Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
    Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
    Chen C; Ju R; Shi J; Chen W; Sun F; Zhu L; Li J; Zhang D; Ye C; Guo L
    J Pharmacol Exp Ther; 2017 Aug; 362(2):219-229. PubMed ID: 28515157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling.
    Kumar BN; Rajput S; Dey KK; Parekh A; Das S; Mazumdar A; Mandal M
    BMC Cancer; 2013 Jun; 13():273. PubMed ID: 23731702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
    Fulzele SV; Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2006 Mar; 58(3):327-36. PubMed ID: 16536899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
    Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Singh M
    Pharm Res; 2006 Sep; 23(9):2094-106. PubMed ID: 16902813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
    Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
    Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
    Winters ME; Mehta AI; Petricoin EF; Kohn EC; Liotta LA
    Cancer Res; 2005 May; 65(9):3853-60. PubMed ID: 15867384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
    Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ
    Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.